ImmunoPrecise Antibodies Ltd.
IPA.V
Toronto Stock Exchange Ventures6.50
CAD
+0.05
- -
ImmunoPrecise Antibodies Ltd.
IPA.V
(Toronto Stock Exchange Ventures)
Recent
price
6.50
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- ImmunoPrecise Antibodies Ltd. is a biotechnology company specializing in therapeutic antibody discovery and development services. The company provides a comprehensive suite of products and services including antibody discovery platforms utilizing hybridoma, B-cell, and phage display technologies; immunization technologies across diverse species and strains; antigen design and modeling; protein expression and purification using proprietary platforms; antibody characterization, engineering, and optimization; affinity maturation and humanization; developability studies; stable cell line development; and cryopreservation and storage services. These offerings enable pharmaceutical and biotechnology companies to accelerate the discovery and development of novel therapeutic antibodies against a wide range of disease targets. ImmunoPrecise operates globally with a focus on serving pharmaceutical and biotech partners through both wet lab and AI-driven technologies. Its proprietary LENSai™ platform integrates bio-native artificial intelligence with laboratory validation, facilitating efficient antibody discovery and predictive immunogenicity screening. The company’s business segments include its BioStrand division, which has shown rapid growth and high margins. Headquartered in Canada and founded in 2012, ImmunoPrecise's operations previously included a Netherlands subsidiary focused on antibody discovery and protein manufacturing. Recent strategic changes include the divestiture of its Netherlands subsidiary, IPA Europe, sold to AVS Bio for $12 million USD in 2025 to streamline operations and focus on its AI-based SaaS platform. The company reported record fiscal year 2025 revenue of $24.5 million, driven by strong growth in AI-enhanced antibody discovery and BioStrand services. ImmunoPrecise secured a strategic partnership valued between $8 million and $10 million for developing antibody-drug conjugates and advanced its universal dengue vaccine program using the LENSai platform, moving toward preclinical in vivo testing. Additionally, the company launched AI-designed GLP-1 therapies enhancing efficacy and safety profiles. These developments underscore a strategic realignment towards AI-driven product development and biotherapeutic innovation. ImmunoPrecise continues to target pharmaceutical, biotech, and diagnostic markets worldwide, leveraging a growing portfolio of antibody discovery and development technologies and strategic collaborations to strengthen its position as an integrated antibody solutions provider. This description reflects the company’s comprehensive service offerings, key recent transactions, strategic focus on AI-driven innovation, and global biopharmaceutical industry engagement as of late 2025.